Calculated prostate cancer volume: The optimal predictor of actual cancer volume and pathologic stage

被引:38
作者
DAmico, AV
Chang, HN
Holupka, E
Renshaw, A
Desjarden, A
Chen, MH
Loughlin, KR
Richie, JP
机构
[1] HARVARD UNIV, SCH MED, JOINT CTR RADIAT THERAPY, 330 BROOKLINE AVE, 5TH FLOOR, BOSTON, MA 02215 USA
[2] BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA
[3] BRIGHAM & WOMENS HOSP, DEPT UROL, BOSTON, MA 02115 USA
[4] WORCESTER POLYTECH INST, DEPT MATH SCI, BOSTON, MA USA
[5] WORCESTER POLYTECH INST, DEPT MATH SCI, WORCESTER, MA 01609 USA
关键词
D O I
10.1016/S0090-4295(96)00509-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. A new clinical pretreatment quantity called the calculated prostate cancer volume has been defined. The correlation between the calculated parameter and the actual prostate cancer volume, and its ability to predict for pathologic Stage T3 disease in patients with clinically localized disease, is tested. Methods. Prostate cancer volume measurements were obtained using a 3-dimensional computerized morphometric reconstruction technique on 104 whole;mounted radical prostatectomy specimens. The calculated prostate cancer volume was determined based on pretreatment clinical parameters (prostate-specific antigen [PSA], biopsy Gleason score, and prostate ultrasound volume). Linear regression was used to determine the Pearson correlation coefficients (r) between the PSA, the calculated prostate cancer volume, and the measured prostate cancer volume. Logistic regression multivariable analysis evaluating the predictive value of the pretreatment PSA, biopsy Gleason score, clinical stage, and calculated prostate cancer volume in predicting pathologic Stage T3 disease in patients with clinically organ-confined disease was performed. Results. The calculated prostate cancer volume (r 0.71 to 0.96) was superior to PSA (r 0.12 to 0.67) in predicting the measured prostate cancer volume over a wide range (0.02 to 9.5 cm(3)) of cancer volumes. The calculated prostate cancer volume was the only significant predictor (P = 0.02) of pathologic Stage T3 disease in patients with clinical Stage T1 to T2 disease on multivariable analysis. Conclusions. The calculated volume of prostate cancer is superior to PSA in predicting both the pathologic prostate cancer volume and pathologic Stage T3 disease in patients with clinical Stage T1 and T2 disease, Therefore, it may be useful in determining the optimal candidates for radical prostatectomy. (C) 1997, Elsevier Science Inc.
引用
收藏
页码:385 / 391
页数:7
相关论文
共 26 条
[1]   PROSTATE-SPECIFIC ANTIGEN AND GLEASON GRADE - AN IMMUNOHISTOCHEMICAL STUDY OF PROSTATE-CANCER [J].
AIHARA, M ;
LEBOVITZ, RM ;
WHEELER, TM ;
KINNER, BM ;
OHORI, M ;
SCARDINO, PT .
JOURNAL OF UROLOGY, 1994, 151 (06) :1558-1564
[2]  
[Anonymous], 1992, American Joint Committee on Cancer Staging Manual
[3]  
[Anonymous], UROLOGIC PATHOLOGY
[4]   TUMOR VOLUME AND PROSTATE-SPECIFIC ANTIGEN - IMPLICATIONS FOR EARLY DETECTION AND DEFINING A WINDOW OF CURABILITY [J].
BABAIAN, RJ ;
TRONCOSO, P ;
STEELHAMMER, LC ;
LLORETATRULL, J ;
RAMIREZ, EI .
JOURNAL OF UROLOGY, 1995, 154 (05) :1808-1812
[5]   THE USE OF PROSTATE SPECIFIC ANTIGEN DENSITY TO ENHANCE THE PREDICTIVE VALUE OF INTERMEDIATE LEVELS OF SERUM PROSTATE SPECIFIC ANTIGEN [J].
BENSON, MC ;
WHANG, IS ;
OLSSON, CA ;
MCMAHON, DJ ;
COONER, WH .
JOURNAL OF UROLOGY, 1992, 147 (03) :817-821
[6]   COMBINING PROSTATE-SPECIFIC ANTIGEN WITH CANCER AND GLAND VOLUME TO PREDICT MORE RELIABLY PATHOLOGICAL STAGE - THE INFLUENCE OF PROSTATE-SPECIFIC ANTIGEN CANCER DENSITY [J].
BLACKWELL, KL ;
BOSTWICK, DG ;
MYERS, RP ;
ZINCKE, H ;
OESTERLING, JE .
JOURNAL OF UROLOGY, 1994, 151 (06) :1565-1570
[7]   LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE [J].
CARTER, HB ;
PEARSON, JD ;
METTER, J ;
BRANT, LJ ;
CHAN, DW ;
ANDRES, R ;
FOZARD, JL ;
WALSH, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16) :2215-2220
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]   Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy [J].
DAmico, AV ;
Propert, KJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (02) :273-279
[10]  
DAMICO AV, 1993, CANCER-AM CANCER SOC, V72, P2638, DOI 10.1002/1097-0142(19931101)72:9<2638::AID-CNCR2820720919>3.0.CO